Cargando…

Targeting Bcl-2/Bcl-X(L) Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts

PURPOSE: Uveal melanoma (UM) is associated with a high risk of metastases and lack of efficient therapies. Reduced capacity for apoptosis induction by chemotherapies is one obstacle to efficient treatments. Human UM is characterized by high expression of the anti-apoptotic protein Bcl-2. Consequentl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Némati, Fariba, de Montrion, Catherine, Lang, Guillaume, Kraus-Berthier, Laurence, Carita, Guillaume, Sastre-Garau, Xavier, Berniard, Aurélie, Vallerand, David, Geneste, Olivier, de Plater, Ludmilla, Pierré, Alain, Lockhart, Brian, Desjardins, Laurence, Piperno-Neumann, Sophie, Depil, Stéphane, Decaudin, Didier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3890263/ https://www.ncbi.nlm.nih.gov/pubmed/24454684 http://dx.doi.org/10.1371/journal.pone.0080836

Ejemplares similares

Radiosensitization by a novel Bcl-2 and Bcl-X(L) inhibitor S44563 in small-cell lung cancer
por: Loriot, Y, et al.
Publicado: (2014)

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
por: de Koning, Leanne, et al.
Publicado: (2019)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
por: Carita, Guillaume, et al.
Publicado: (2016)

Upcoming translational challenges for uveal melanoma
por: Nabil, Amirouchene-Angelozzi, et al.
Publicado: (2015)

Upcoming translational challenges for uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2015)

Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma
por: Cassoux, Nathalie, et al.
Publicado: (2014)

Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells
por: Bellini, Lara, et al.
Publicado: (2020)

Low expression of bcl-2 in Brca1-associated breast cancers
por: Freneaux, P, et al.
Publicado: (2000)

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2018)

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
por: Groenewoud, Arwin, et al.
Publicado: (2023)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023)

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
por: Nemati, Fariba, et al.
Publicado: (2023)

Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1
por: Mena, Salvador, et al.
Publicado: (2012)

Bcl-B: an “unknown” protein of the Bcl-2 family
por: Pervushin, N. V., et al.
Publicado: (2023)

Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022)

Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI
por: Mariani, Pascale, et al.
Publicado: (2019)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

Bcl-2 family member Bcl-G is not a proapoptotic protein
por: Giam, M, et al.
Publicado: (2012)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Zeaxanthin Induces Apoptosis in Human Uveal Melanoma Cells through Bcl-2 Family Proteins and Intrinsic Apoptosis Pathway
por: Bi, Ming-Chao, et al.
Publicado: (2013)

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
por: Casara, Patrick, et al.
Publicado: (2018)

Bcl-XL and Bcl-2 repress a common pathway of cell death
Publicado: (1995)

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
por: Mahmoud, Hanan Mohamed, et al.
Publicado: (2011)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma
por: Gentien, David, et al.
Publicado: (2023)

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes
por: van Essen, T. Huibertus, et al.
Publicado: (2016)

Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the mitochondrial outer membrane
por: Kaufmann, Thomas, et al.
Publicado: (2003)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-2 and Bcl-x(L) Suppress Glucose Signaling in Pancreatic β-Cells
por: Luciani, Dan S., et al.
Publicado: (2013)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

BCL9/BCL9L in hepatocellular carcinoma: Will it or Wnt it be the next therapeutic target?
por: Moghe, Akshata, et al.
Publicado: (2020)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

Role of MicroRNA-182 in Posterior Uveal Melanoma: Regulation of Tumor Development through MITF, BCL2 and Cyclin D2
por: Yan, Dongsheng, et al.
Publicado: (2012)

Upregulation of BCL2 19 kD Protein-Interacting Protein 3 (BNIP3) is Predictive of Unfavorable Prognosis in Uveal Melanoma
por: Jiang, Zhongming, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_23tc9jjkido0nentlebnvqujv2